Author | Kuriyama, Sergio N. | |
Author | Farjun, Bruna | |
Author | Henriques-Santos, Bianca Monteiro | |
Author | Cabanelas, Adriana | |
Author | Abrantes, Juliana Lourenço | |
Author | Gesto, João | |
Author | Fidalgo Neto, Antonio A. | |
Author | Souza, Thiago Moreno L. | |
Access date | 2022-07-04T12:17:13Z | |
Available date | 2022-07-04T12:17:13Z | |
Document date | 2022 | |
Citation | KURIYAMA, Sergio N. et al. SARS-CoV-2 Molecular Epidemiology Can Be Enhanced by Occupational Health: The Experience of Monitoring Variants of Concern in Workplaces in Rio de Janeiro, Brazil. Frontiers in Medicine, v.9, Article 862284, p. 1 - 7, Apr. 2022. | pt_BR |
ISSN | 2298-858X | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/53623 | |
Language | eng | pt_BR |
Publisher | Frontiers Media | pt_BR |
Rights | open access | pt_BR |
Subject in Portuguese | COVID-19 | pt_BR |
Subject in Portuguese | SARS-CoV-2 | pt_BR |
Subject in Portuguese | Assistência médica ocupacional | pt_BR |
Subject in Portuguese | Vigilância | pt_BR |
Subject in Portuguese | Variantes de preocupação (VOCs) | pt_BR |
Subject in Portuguese | Sequência molecular | pt_BR |
Subject in Portuguese | Sequenciamento (NGS) de próxima geração (profundo) | pt_BR |
Title | SARS-CoV-2 Molecular Epidemiology Can Be Enhanced by Occupational Health: The Experience of Monitoring Variants of Concern in Workplaces in Rio de Janeiro, Brazil | pt_BR |
Type | Article | pt_BR |
DOI | 10.3389/fmed.2022.862284 | |
Abstract | The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has led to extra caution in workplaces to avoid the coronavirus disease 2019 (COVID-19).
In the occupational environment, SARS-CoV-2 testing is a powerful approach in providing
valuable information to detect, monitor, and mitigate the spread of the virus and preserve
productivity. Here a centralized Occupational Health Center providedmolecular diagnosis
and genomic sequences for companies and industries in Rio de Janeiro, Brazil. From
May to August 2021, around 20% of the SARS-CoV-2 positive nasopharyngeal swabs
from routinely tested workers were sequenced and reproduced the replacement of
Gamma with Delta variant observed in regular surveillance programs. Moreover, as
a proof-of-concept on the sensibility of the occupational health genomic surveillance
program described here, it was also found: i) the primo-identification of B.1.139 and
A.2.5 viral genomes in Brazil and ii) an improved dating of Delta VoC evolution, by
identifying earlier cases associated with AY-related genomes. We interpret that SARS-
CoV-2 molecular testing of workers, independent of symptom presentation, provides an
earlier opportunity to identify variants. Thus, considering the continuous monitoring of
SARS-CoV-2 in workplaces, positive samples from occupation health programs should
be regarded as essential to improve the knowledge on virus genetic diversity and
VoC emergence. | pt_BR |
Affilliation | Centro de Inovação SESI em Saúde do Trabalhador. Rio de Janeiro, RJ, Brasil / Instituto SENAI de Inovação em Química Verde, Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Centro de Inovação SESI em Saúde do Trabalhador. Rio de Janeiro, RJ, Brasil / Instituto SENAI de Inovação em Química Verde, Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Centro de Inovação SESI em Saúde do Trabalhador. Rio de Janeiro, RJ, Brasil / Instituto SENAI de Inovação em Química Verde, Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Centro de Inovação SESI em Saúde do Trabalhador. Rio de Janeiro, RJ, Brasil / Instituto SENAI de Inovação em Química Verde, Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Ciências Biomédicas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Instituto SENAI de Inovação em Química Verde. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Centro de Inovação SESI em Saúde do Trabalhador. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia para Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | COVID-19 | pt_BR |
Subject | SARS-CoV-2 | pt_BR |
Subject | Occupational medical care | pt_BR |
Subject | Surveillance | pt_BR |
Subject | Variants of concern (VOCs) | pt_BR |
Subject | Molecular sequence | pt_BR |
Subject | Next generation (deep) sequencing (NGS) | pt_BR |